Cetuximab

Colorectal Cancer

Cetuximab is used to treat colorectal cancer that has spread to other parts of the body (metastatic). It is typically used for tumors that express the epidermal growth factor receptor (EGFR). It may be prescribed in the following situations:

• In combination with chemotherapy as an initial treatment.
• By itself if previous chemotherapy treatments have failed.
• In combination with other targeted drugs for tumors with specific genetic mutations, such as BRAF V600E or KRAS G12C.

Testing is usually required before treatment to confirm the tumor's genetic profile, as the drug is generally not effective for tumors with certain RAS mutations.

Head and Neck Cancer

This medication is used to treat a type of head and neck cancer called squamous cell carcinoma. It may be used in several ways:

• With radiation therapy for cancer that is locally or regionally advanced.
• In combination with platinum-based chemotherapy for cancer that has spread or returned.
• As a single agent for cancer that has returned or spread and did not respond to platinum-based chemotherapy.

Targeting Cancer Cells

Cetuximab is a type of targeted therapy known as a monoclonal antibody. These are laboratory-made proteins designed to recognize and attach to specific structures on the surface of cells.

How It Works

This medication specifically targets a protein called the epidermal growth factor receptor (EGFR). EGFR is found on the surface of many normal cells, but it is often present in much higher amounts on certain types of cancer cells, including those in the head, neck, colon, and rectum.

When cetuximab attaches to these receptors, it interferes with the cancer's ability to grow in the following ways:

• Blocking Growth Signals: It physically binds to the EGFR, preventing natural growth factors in the body from reaching the receptor. This blocks the chemical signals that tell the cancer cell to grow and divide.
• Slowing Tumor Progression: By interrupting these signals, the medication can help shrink tumors or prevent them from spreading further.
• Enhancing Other Treatments: Cetuximab may be used alone or in combination with radiation therapy or chemotherapy to help make the overall treatment more effective against cancer cells.

Because cetuximab targets a specific protein, it is designed to be more precise than traditional chemotherapy, although it can still affect some healthy cells that also carry the EGFR protein.

Common Side Effects

Many people receiving cetuximab experience mild to moderate side effects. These may include:

• Skin changes, such as an acne-like rash, dryness, itching, or cracking
• Changes in fingernails or toenails
• Feeling tired or weak
• Nausea, vomiting, or stomach pain
• Diarrhea or constipation
• Loss of appetite and weight loss
• Headache
• Cough or sore throat
• Fever

Serious Side Effects

Some side effects can be severe. Contact a healthcare provider immediately if you experience:

• Signs of an infusion reaction, such as chills, fever, dizziness, or difficulty breathing during or after treatment
• Severe skin reactions, including blistering, peeling, or signs of infection
• Sudden chest pain or shortness of breath
• Vision changes or eye pain
• Signs of low magnesium or other electrolyte imbalances, such as muscle cramps, shakiness, or an irregular heartbeat
• Swelling of the hands, ankles, or feet

Exposure to sunlight can make skin rashes worse. It is often recommended to limit sun exposure and use protective clothing or sunscreen while using this medication.

Infusion Reactions

Severe and potentially life-threatening infusion reactions can occur. These reactions may happen during the first infusion or later in treatment. Healthcare providers monitor patients during the procedure and for a period afterward to watch for signs like difficulty breathing, low blood pressure, or swelling of the face and throat.

Cardiopulmonary Risks

There is a risk of sudden death or the heart and lungs stopping (cardiopulmonary arrest). This risk may be higher when cetuximab is used in combination with radiation therapy or other chemotherapy medications. Monitoring of heart function and electrolytes is often necessary, especially for those with a history of heart disease.

Skin and Nail Reactions

Most patients experience skin reactions, which can include an acne-like rash, skin peeling, or infections around the fingernails and toenails. Because sunlight can worsen these reactions, it is important to limit sun exposure and use protective clothing or sunscreen. In some cases, these skin issues can lead to serious infections.

Electrolyte Imbalances

This medication can lead to dangerously low levels of magnesium, potassium, and calcium. These imbalances may not cause symptoms initially, so regular blood monitoring is required. Supplements may be needed to correct these levels during and after treatment.

Lung Complications

Interstitial lung disease, which involves inflammation or scarring of the lung tissue, has been reported. Patients should alert their medical team if they experience new or worsening breathing difficulties or a persistent cough.

Tumor Mutation Status

In colorectal cancer, cetuximab is typically only effective for tumors that do not have certain mutations in the KRAS or NRAS genes. Testing is required before starting treatment to ensure the medication is appropriate for the specific tumor type.

Pregnancy and Reproductive Health

Cetuximab can cause fetal harm if used during pregnancy. Individuals who can become pregnant are typically advised to use effective birth control during treatment and for at least six months after the last dose. Breastfeeding is not recommended during treatment and for two months following the final dose.

Pregnancy

Cetuximab can cause harm to a fetus when administered to a pregnant person. Animal studies have shown that the medication may lead to pregnancy loss or affect the development of the fetus. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this medication.

Individuals who can become pregnant should use effective contraception during treatment with cetuximab and continue using it for at least 2 months after the final dose. If pregnancy occurs during treatment, the potential risk to the fetus should be discussed with a healthcare professional.

Breastfeeding

It is not known whether cetuximab passes into human breast milk. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. It is generally advised to avoid breastfeeding during therapy and for 2 months following the last dose of cetuximab.

Available Forms

Cetuximab is supplied in the following form:

• Intravenous Solution: A sterile, preservative-free liquid intended for infusion into a vein.

This medication is provided in single-use vials and must be administered by a trained medical provider in a clinical setting.

FDA Approval and Indications

Cetuximab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of cancer. Its primary indications include:

• Head and Neck Cancer: It is used to treat squamous cell carcinoma of the head and neck, either in combination with radiation therapy or as a standalone treatment for cancer that has spread.
• Colorectal Cancer: It is approved for metastatic colorectal cancer that expresses the epidermal growth factor receptor (EGFR). It is typically used in patients whose tumors are KRAS wild-type (not mutated).

Recent Accelerated Approvals

The FDA has recently granted accelerated approvals for cetuximab in combination with other medications for specific genetic mutations:

• BRAF V600E Mutation: Approved for use with encorafenib and chemotherapy for adults with metastatic colorectal cancer carrying this specific mutation.
• KRAS G12C Mutation: Approved for use with adagrasib for adults with KRAS G12C-mutated metastatic colorectal cancer who have previously received other treatments.

Boxed Warning and Safety Information

The FDA requires a boxed warning for cetuximab because of the potential for severe adverse events:

• Infusion Reactions: Serious and sometimes fatal infusion reactions can occur. These reactions often happen during the first dose and require immediate medical intervention.
• Cardiopulmonary Arrest: There is a risk of sudden death or heart failure, particularly when the drug is used alongside radiation therapy or other chemotherapy agents.

Patients are typically monitored for at least one hour following each infusion to manage these risks.

Treatment Setting and Administration

Cetuximab is administered as an intravenous infusion by healthcare professionals in a hospital or clinical setting. Because it is not a medication that can be self-administered at home, the total cost of treatment typically includes the price of the drug itself plus fees for the medical facility, equipment, and the professional staff who monitor the infusion.

Factors Influencing Cost

Several variables can affect the overall expense of cetuximab therapy:

• Dosage and Frequency: The amount of medication prescribed and how often it is given (such as weekly or every two weeks) depend on the specific condition being treated and the patient's individual requirements.
• Duration of Treatment: The total cost is impacted by how long the patient continues the therapy as determined by their healthcare provider.
• Insurance Coverage: Coverage for cetuximab varies by insurance provider and plan. Patients are encouraged to contact their insurance company to determine their specific out-of-pocket costs, such as deductibles or copayments.

For more detailed information regarding the price of the medication and administration fees, patients should consult with the billing department of their treatment facility or their healthcare provider.